Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: Complementrituximab interactions & clinical results in refractory CLL

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 865-873

  Klepfish, Abraham ^e   Gilles, Lugassy ^b   Ioannis, Kotsianidis ^c   Eliezer, Rachmilewitz ^a   Ami, Schattner ^d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d HEBREW UNIVERSITY   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

CLL; Complement; Plasma; Rituximab; Treatment resistant

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FRESH FROZEN PLASMA; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ANEMIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER STAGING; CELL LOSS; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPLEMENT DEFICIENCY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FEVER; GREECE; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; ISRAEL; LYMPH NODE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; NIGHT SWEAT; OPEN STUDY; OUTPATIENT DEPARTMENT; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 70049114231     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04803.x     Document Type: Conference Paper

References (38)

1. Chiorazzi, N., K.R. Rai & M. Manlio Ferrarin. 2005. Chronic Lymphocytic Leukemia. NEJM 353: 804-815.
2. Chiorazzi N. & M. Ferrarini. 2006. Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematol. Am. Soc. Hematol. Educ. Program. 273-278.
3. Chronic lymphocytic leukemia. Surveillance Epidemiology and End Results (SEER). National Cancer Institute, US National Institutes of Health, Washington, DC.
4. Kay, N.E., S.M. O'Brien, A.R. Pettitt & S. Stilgen-bauer. 2007. The role of prognostic factors in assessing the "high-risk" subgroups of patients with chronic lymphocytic leukemia. Leukemia 21: 1885-1891.
5. Yee, K.W. & S.M. O'brien. 2006. Chronic lympho-cytic leukemia: diagnosis and treatment. Mayo Clin. Proc. 81: 1105-1129.
6. Keating, M.J., S. O'Brien, H. Kantarjian, et al. 1993. Long-term follow-up of patients with chronic lym-phocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878-84.
7. Cheung, M.C., A.E. Haynes, R.M. Meyer, et al. Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. 2007. Rituximab in lymphoma: a systematic review and concensus practice guideline from Cancer Care Ontario. Cancer Treat. Rev. 33: 161-76.
8. Byrd, J.C., T. Murphy, R.S. Howards, et al. 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19: 2153-2164.
9. Huhn D., C. von Schilling, M. Wilhelm, et al. 2001. Rituximab therapy of patients with chronic lympho-cytic leukemia. Blood 98: 1326-1331.
10. Golay, J., M. Lazzari, V. Facchinetti, et al. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lym-phocytic leukemia: further regulation by CD55 and CD59. Blood 98: 3383-3389.
11. Polliack, A. & G. Lugassy. 1992. Autoimmunity and autoimmune syndromes associated with and preceding the development of lymphoproliferative disorders. Leukemia 6: 152-154.
12. Scrivener, S., R.V. Goddard, F.R. Kaminski & E.G. Prentice. 2003. Abnormal T-cell function in chronic lymphocytic leukaemia. Leuk. Lymphoma 44: 383-389.
13. Miszlai, Z., E. Czink, L.K. Varga, et al. 1986. Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukemia. Acta Med. Hung. 43: 389-395.
14. Hidvegi, R., G.A. Ermolin, E.E. Efremov, et al. 1989. FN-C1q and C1-INH C1r-C1s complexes as indicators of complement activation in patients with chronic lymphocytic leukemia. Immunol. Lett. 22: 1-6.
15. Fust, G., E. Czink, D. Minh, et al. 1985. Depressed classical complement pathway activities in chronic lymphocytic leukemia. Clin. Exp. Immunol. 60: 489-495.
16. Varga, L.K., E. Czink & Z. Miszlai. 1995. Low activity of the classical pathway predicts short survival of patients with chronic lymphocytic leukemia. Clin. Exp. Immunol. 99: 112-116.
17. Schlesinger, M., I. Broman & G. Lugassy. 1996. The Complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 10: 1509-1513.
18. Kennedy, A.D., M.D. Solga, T.A. Schuman, et al. 2003. Anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101: 1071-1079.
19. Kennedy, A.D., P. Beum, M.D. Solga, et al. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
20. Schreiber, A.D. & M.M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51: 575-582.
21. Johnson, P. & M. Glennie. 2003. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30(1 Suppl 2): 3-8.
22. Klepfish, A., A. Schattner, H. Ghoti & E.A. Rach-milewitz. 2007. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 8: 361-362.
23. Keating, M.K., I. Flinn, V. Jain, et al. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561.
24. Tsimberidou, A.M., W.G. Wierda, W. Plunkett, et al. 2008. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 26: 196-203.
25. Johnson P. & M. Glennie. 2003. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30(1 Suppl 2): 3-8.
26. Bonavida, B. 2007. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsive-ness, prognostic and novel therapeutic interventions. Oncogene 26: 3629-3636.
27. van Meerten, T., R.S. van Rijn, S. Hol, et al. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12: 4027-4035.
28. Garćia-Carrasco M., M. Jiménez-Hernández, R.O. Escárcega, et al. 2008. Use of rituximab in patients with systemic lupus erythematosus: An update. Autoimmun. Rev. Nov 23. [Epub ahead of print].
29. Buske, C., M. Dreyling, M. Unterhalt & W. Hidde-mann. 2005. Monoclonal antibody therapy for malignant lymphoma. Review. Med. Klin. (Munich) 100: 14-24.
30. Osterborg, A, T.J. Kipps, J. Mayer, et al. 2008. Ofatu-mumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts), 112: Abstract # 328.
31. Hallek, M., G. Fingerle-Rowson, A.M. Fink, et al. Im-munochemotherapy with fludarabine (F), cyclophos-phamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lym-phocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 112: Abstract #3
32. Saadoun, D., A. Delluc, J.C. Piette & P. Cacoub. 2008. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr. Opin. Rheumatol. 20: 23-28.
33. Isaksen K., R. Jonsson & R. Omdal. 2008. Anti-CD20 treatment in primary Sjögren's syndrome. Scand. J. Immunol. 68: 554-564.
34. Czuczman, M.S., C. Emmanouilides, M. Darif, et al. 2007. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol. 25: 4285-92.
35. Faderl, S., A. Ferrajoli, O. Frankfurt & A. Pettitt. 2008. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: expe rience with single-agent and combination therapy. Leukemia Nov 6. [Epub ahead of print].
36. Zent, C.S., C.R. Secreto, B.R. LaPlant, et al. 2008. Direct and complement dependent cytotoxic-ity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treatedwith alemtuzumab and rituximab. Leuk. Res. 32: 1849-1856. Epub 2008 Jun 27.
37. de Romeuf, C., C.A. Dutertre, M. Le Garff-Taver ni er, et al. 2008. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br. J. Haematol. 140: 635-643.
38. Ayuk, F.A., N. Atassi, G. Schuch, et al. 2008. Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk. Res. 32: 1200-1206. Epub 2008 Feb 4.